Skip to content
Screener

Candel Therapeutics, Inc. CADL Q2 2025 earnings

Reported August 14, 2025 · Before market open

EPS-$0.09Beat by $0.08
EPS estimate-$0.17

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.30

Financials

Q2 2025

Income statement

See full
Operating income-$11.2M-30.4%
Net income-$4.8M+78.4%
EPS (diluted)-$0.09+87.8%

Balance sheet

See full
Cash & equivalents$100.7M+369%
Total debt$8.3M-29.6%
Total equity$90.2M+1,005%
Total assets$106.0M+300%

Cash flow

See full
Operating cash flow-$8.9M-43.4%
CapEx$31.0K+417%
Free cash flow-$8.9M-43.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$243M+34.2%
Enterprise value$150.65M-12.1%

Returns & leverage

See full
Debt / equity0.1×—
Current ratio7×+5.4×

FAQ

When did Candel Therapeutics, Inc. report Q2 2025 earnings?
Candel Therapeutics, Inc. (CADL) reported Q2 2025 earnings on August 14, 2025 before market open.
What were Candel Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.09 for Q2 2025.
Did Candel Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.17 by $0.08.
How did Candel Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 87.8% from $-0.74.
Where can I find Candel Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-108448) and the 10-Q periodic report (0000950170-25-108450) directly on SEC EDGAR. The filing index links above go to sec.gov.